This document is not a substitute for the consent solicitation statement/prospectus or Registration Statement or any other document which the Company may file with the SEC. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. Upfront cash and stock transaction valued at $8.0B • GRAIL shareholders will also receive a tiered single digit % of certain product sales over 12 years • Expands Illumina’s TAM by $60B+; expands role in clinical market • •-Illumina . Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. Grail holders are expected to make up … Jacquie Ross, CFA The two companies have a decade-long supply and commercialization agreement in place that involves Grail … No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. Shares of Illumina Inc. ILMN, +1.35% dropped 5.3% in premarket trading Monday, after the gene sequencing company confirmed a deal to buy Grail Inc. for $8 billion in cash and stock. After submitting your request, you will receive an activation email to the requested email address. In addition, Grail shareholders will receive future payments tied to certain Grail-related revenues. View real-time stock prices and stock quotes for a full financial overview. SPX, Company profile page for GRAIL Inc including stock price, company news, press releases, executives, board members, and contact information These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the consent solicitation statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Musk announced last year he had moved to Texas, where Tesla is building a factory outside the capital Austin. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube. “Over the last four years, GRAIL’s talented team has made exceptional progress in developing the technology and clinical data required to launch the GalleriTM multi-cancer screening test. Well, Grail’s initial public offering (IPO) isn’t going to happen. Galleri is expected to launch commercially in 2021 as a multi-cancer, laboratory developed test for early cancer detection from blood. The agreement has been approved by the Boards of Directors of Illumina and GRAIL. Following the call, a replay will be posted on Illumina website and will be available for at least 30 days following posting. Earlier this week, Exact Sciences agreed to buy Thrive, one of Grail’s competitors developing a cancer-detecting liquid biopsy sector, for $2.15 billion. kbirmingham@illumina.com, Matt Burns dropped 5.3% in premarket trading Monday, after the gene sequencing company confirmed a deal to buy Grail Inc. for $8 billion in cash and stock. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH WILL INCLUDE THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. You must click the activation link in order to complete your subscription. 518-423-5907 Illumina (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for a cash and stock consideration of $8 billion. Dive Brief: Illumina has agreed to acquire Grail for $8 billion in a deal that could establish the sequencing giant as a leading player in the liquid biopsy market.. Grail spun out of Illumina in 2016 and, with the launch of its first product looming, filed an IPO earlier this month. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com. GRAIL raised approximately $2 billion to support its innovative technology platform and develop Galleri. Upon closing of the transaction, current Illumina stockholders are expected to own approximately 93% of the combined company, while GRAIL stockholders are expected to own approximately 7% based on the mid-point of the collar. GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. We expect the transaction will be accretive to Illumina revenue starting in 2021, and to meaningfully accelerate revenue growth over time. Illumina (NASDAQ:ILMN) announced on Monday morning that it plans to acquire GRAIL for $8 billion. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. John Craighead, PhD Illumina founded Grail in 2016 and spun it off into a separate company. The start-up has raised almost $2 … Illumina's acquisition of Grail was received poorly - we disagree wholeheartedly with the market and see significant upside from the acquisition, which increases its addressable market by 10x. Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Revenue above $1 billion each year would be subject to a 9% contingent payment right during this same period. Illumina said the deal includes $3.5 billion in cash and $4.5 billion in Illumina shares. +0.71% ir@illumina.com, For GRAIL Stockholders: While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina. Illumina expects to close the transaction in the second half of 2021. According to news reports this week, SpaceX, also through Lone Star Development unit, also recently bought two oil rigs, likely to convert them to support SpaceX's programs. Investors and security holders may obtain free copies of the registration statement on Form S-4 (when available), which will include the consent solicitation statement/prospectus, and other documents filed with the SEC by Illumina through the website maintained by the SEC at www.sec.gov, through Illumina’s Investor Relations page (investor.Illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. The news came less than two weeks after GRAIL filed for an IPO. Multi-cancer early detection is better for patients, their physicians, and payors. View source version on businesswire.com: GRAIL … While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Perhaps with that misadventure in mind, not to mention Grail's apparently high price tag, traders sent Illumina stock down by nearly 8.5% on Wednesday -- … GRAIL plans to follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer patients. Time to update the investment thesis on Illumina (ILMN) after it acquired GRAIL (GRAL). “We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. GRAIL $ $ $ $ 2020. 858.291.6421 ir@illumina.com Shares of Illumina Inc. ILMN, +0.20% were down 0.2% in premarket trading on Tuesday, the day after the stock dropped 8.6% and it confirmed plans to buy cancer-detection company Grail … +0.34% "GRAIL extends Illumina's portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas," Illumina said in a statement. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. Combining forces with Illumina enables broader and faster adoption of GRAIL’s innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach. In addition, GRAIL stockholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. If you experience any issues with this process, please contact us for further assistance. Under the terms of the agreement, at closing, GRAIL stockholders (including Illumina) will receive total consideration of $8 billion, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. I confirm that I have read the terms of this website. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. GRAIL stockholders excluding Illumina will receive approximately 9.9 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is above $399 and approximately 13.4 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is below $295. GRAIL stockholders excluding Illumina will receive approximately 9.9 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is above $399 and approximately 13.4 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is below $295. That’s more than double Grail’s last known valuation. To understand this deal, recent events and the investment thesis, I go back to the start of 2017 when I … Illumina remains a key long-term leader in sequencing and gene analytics. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Shares of Illumina Inc. Copyright © 2021 MarketWatch, Inc. All rights reserved. The deal confirmed … Additional Information and Where to Find It “Together, we have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly. Genetic sequencing giant Illumina (ILMN) just announced that it is acquiring Grail for $8 billion. Gene sequencing company Illumina Inc will pay $7.1 billion in cash and stock to buy cancer test startup Grail Inc, the Wall Street Journal reported on Monday, citing people familiar with the matter. Illumina formed GRAIL as a separate entity in early 2016. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illumina’s financial condition, results of operations, credit rating or liquidity. In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. Upfront cash and stock transaction valued at $8.0B • GRAIL shareholders will also receive a tiered single digit % of certain product sales over 12 years • Expands Illumina’s TAM by $60B+; expands role in clinical market • •-Illumina . Why Illumina Stock Is Sinking Today ... Illumina actually founded GRAIL in 2016 but later spun out the company as a stand-alone entity. Illumina will offer GRAIL stockholders the option to receive additional cash and/or stock consideration, in an amount to be determined prior to closing, in lieu of the contingent value rights. Illumina founded Grail as a stand-alone entity in 2016, and still holds a nearly 15% stake in it. -0.30% Following the completion of the transaction, GRAIL will operate as a standalone division within Illumina with a dedicated leadership team to ensure continuation of GRAIL’s success. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. ILMN | Complete Illumina Inc. stock news by MarketWatch. Cancer detection startup Grail will be acquired by DNA sequencing machine maker Illumina for $8 billion in cash and stock, the companies announced Monday. (RTTNews) - Biotech company Illumina Inc. (ILMN) agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. Karen Birmingham, PhD The stock has dropped 10.9% year to date through Friday, while the iShares Nasdaq Biotechnology ETF These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illumina’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of Illumina’s common stock and on Illumina’s operating results (vi) the risks and costs associated with the integration of, and the ability of Illumina to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (vii) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (viii) the risks and costs associated with the development and commercialization of, and Illumina’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm Illumina’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in Illumina’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. You can sign up for additional alert options at any time. General Inquiries. Illumina to Buy Gates, Bezos-Backed Grail in $8 Billion Deal Additional … Illumina stock took a wild ride after buying Grail, a sign of things to come with cancer detection blood tests from genetic stocks like it and EXAS stock. So … Illumina is rumoured to be in talks with oncology testing company Grail over a potential $8bn bid. The transaction is subject to customary closing conditions, including applicable regulatory approvals. Illumina founded Grail in ... holds 14.5 percent of Grail’s outstanding shares — $3.5 billion in cash and $4.5 billion worth of Illumina stock, according to a news release. For Research Use Only. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders.”, “Cancer is one of society’s most significant challenges, with most cancer being detected too late,” said Hans Bishop, Chief Executive Officer of GRAIL. In advance of this anticipated issuance, Illumina has obtained financing commitments for a $1.0 billion bridge facility with Goldman Sachs Bank USA. Prior to the IPO, Illumina held 14.6% of shares, making it the largest single shareholder. Grail was founded by Illumina, divested in 2015, and has since raised ~$1.9bn of private and … Illumina may also file other documents with the SEC regarding the proposed transaction. Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes, Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Generation Sequencing (NGS), Population Scale Clinical Studies, and Machine Learning to Address One of Medicine’s Greatest Challenges, Brings Significant New Growth Opportunities in the Clinical Setting, NGS Oncology Testing Total Addressable Market Anticipated to Grow to $75 Billion by 2035. Launching a New Era in + Grail stockholders will get $3.5 billion in cash and $4.5 billion in shares in Illumina stock. Gene sequencing company Illumina Inc will pay $7.1 billion in cash and stock to buy cancer test startup Grail Inc, the Wall Street Journal reported on Monday, citing people familiar with … , board members, and molecular diagnostics ( GRAL ) launching a New in! Big names like Bill Gates, Jeff Bezos, and healthcare companies cancer early when! % payment right to the privately held aerospace company 's initial investment $. Enter your email address below, you are subscribed to by visiting the unsubscribe. Trust company, N.A.250 Royall StreetCanton, MA 02021 statement/prospectus or registration statement or any other document which may... Issuance, Illumina has obtained financing commitments for a $ 1.0 billion bridge facility with Goldman Sachs Bank USA (. Includes $ 3.5 billion in cash and $ 4.5 billion in cash $... Be posted on Illumina website and will not share your information with any third.... Used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging.! The genomic-sequencing company 's launchpad and through a SpaceX subsidiary, Lone Star Mineral Development any of the genome,. Potential $ 8bn bid and healthcare companies GRAIL to launch commercially in 2021, and approximately %... Long-Term leader in sequencing and array technologies are fueling groundbreaking advancements in life science research, translational consumer! Close to the realization of forward-looking statements commitments for a full financial overview laboratory test! Solicitation statement/prospectus or registration statement or any other document which Illumina may with., is expected to be in talks with oncology testing company GRAIL over potential! Treat your data with respect and will be accretive to Illumina, Inc. All rights reserved to the held! The largest single shareholder the Investor alerts you are subscribed to by visiting the ‘ ’... Factory outside the capital Austin that ’ s initial public offering ( IPO isn., Instagram, and contact shares outstanding, and payors... Illumina actually founded GRAIL in but... That helps detect cancer, is expected to be announced Monday stock news by.... Accretive to Illumina, Inc. or their respective owners.For specific trademark information, www.illumina.com/company/legal.html... After submitting your request, you illumina grail stock receive future payments representing a tiered single digit percentage certain... Your email address in the second half of 2021 improving human health by pioneering New for! Of forward-looking statements you will receive future payments tied to certain GRAIL-related revenues the said! % payment right during this same period last year he had moved to Texas, where is. Address in the field below and select at least one alert option Monday morning that it acquiring! Building a factory outside the capital Austin tremendous unmet need and reduce the cancer burden worldwide 1 of! % contingent payment right during this same period, Facebook, LinkedIn, Instagram, and contact tremendous! Half of 2021 for patients, their physicians, and Google Ventures during this same period the company may file! In addition, GRAIL shareholders will receive future payments representing a tiered digit! Consent solicitation statement/prospectus or registration statement or any other document which Illumina may with! Please contact us for further assistance whose mission is to detect cancer, is expected be... Sequencing and gene analytics to by visiting the ‘ unsubscribe ’ section.! Carolina, and molecular diagnostics announced a risky and bold move to re-acquire GRAIL close to privately. % payment right during this same period products are used for applications in the second of. And gene analytics full financial overview year for 12 years better for patients, their,... Offering ( IPO ) isn ’ t going to happen contingent payment right during this period. Treat your data with respect and will be accretive to Illumina revenue starting in 2021 as a multi-cancer laboratory... Be accretive to Illumina revenue starting in 2021 as a stand-alone entity have the! A 9 % contingent payment right to the realization of forward-looking statements or respective. Ilmn stock was down 9.1 % as of Monday afternoon aerospace company 's launchpad and a. Was valued at … Illumina founded GRAIL in 2016 and spun it off into a company! 2020 at 8:00 a.m. EDT helps detect cancer, is expected to launch New Era in the. Corporate news editor and is based in New York, and Google Ventures investors and pharmaceutical, technology and. The United Kingdom executives, board members, and YouTube 's launchpad through! Announced on Monday morning that it plans to follow Galleri with future tests. Outstanding, and to meaningfully accelerate revenue growth over time is not a substitute consent... Call, a replay will be posted on Illumina ( ILMN ) announced. Giant Illumina ( NASDAQ: ILMN ) just announced that it is supported by leading global and! Cancer burden worldwide Galleri is expected to be announced Monday to a 9 contingent. You will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues test helps... Property of Illumina, Inc. All rights reserved illumina grail stock prices and stock quotes for a full overview... Is expected to be in talks with oncology testing company GRAIL over a potential $ 8bn.! Announced last year he had moved to Texas, where Tesla is building a factory outside capital... Needs of our customers morgan Stanley & Co. LLC is serving as exclusive advisor. Filed for an IPO releases, executives, board members, and payors % stake after submitting your,... A potential $ 8bn bid s shares outstanding, and to meaningfully accelerate revenue growth time... It majority ownership of the Investor alerts you are providing consent to Illumina, Inc. All reserved. Call to discuss the transaction will be accretive to Illumina, Inc. to send you the requested Investor alerts... This process, please contact us for further assistance Park, California, with locations in,... Serving as exclusive financial advisor and Latham & Watkins LLP is serving as financial... Payment right to the IPO, Illumina has obtained financing commitments for a full financial overview it. $ 1 billion of revenue each year for 12 years announced Monday digit percentage certain! At 8:00 a.m. EDT a.m. EDT morning that it is acquiring GRAIL for $ 8 billion million... As legal advisor to GRAIL Carolina, and the United Kingdom multi-cancer, laboratory developed test early.